giredestrant
优于标准疗法 罗氏口服乳腺癌新药giredestran三期成功
罗氏 evERA 三期试验达成共同主要终点：giredestrant合依维莫司在 ER+/HER2- 转移性乳腺癌中显著改善 PFS，尤其对 ESR1 突变人群疗效突出。结果有望改变 CDK4/6 失败后的临床治疗格局。
giredestrant
罗氏 evERA 三期试验达成共同主要终点：giredestrant合依维莫司在 ER+/HER2- 转移性乳腺癌中显著改善 PFS，尤其对 ESR1 突变人群疗效突出。结果有望改变 CDK4/6 失败后的临床治疗格局。
giredestrant
Roche’s Phase III evERA trial met its co-primary endpoints, with giredestrant + everolimus delivering significant PFS benefit in ER+/HER2- metastatic breast cancer after CDK4/6 inhibitor therapy. Results mark the first positive late-stage head-to-head study of an oral SERD regimen in this setting.